Specify Company / Ticker to Get the Summary
Dividend History PEPG
Dividend Analytics PEPG
Max Ratio
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–PepGen Ltd
PEPGPepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts. Address: 321 Harrison Avenue, Boston, MA, United States, 02118
Analytics
WallStreet Target Price
8.00 USDP/E Ratio
–Dividend Yield
–Financials PEPG
Results | 2019 | Dynamics |